118 related articles for article (PubMed ID: 29469718)
41. [Eccrine squamous syringometaplasia and cytomegalovirus infection].
Baysse L; Boralevi F; Lepreux S; Boyer A; Morel C; Léauté-Labrèze C; Taïeb A
Rev Med Interne; 2003 Jun; 24(6):394-8. PubMed ID: 12814829
[TBL] [Abstract][Full Text] [Related]
42. Syringometaplasia: mucinous and squamous variants.
King DT; Barr RJ
J Cutan Pathol; 1979 Aug; 6(4):284-91. PubMed ID: 500875
[TBL] [Abstract][Full Text] [Related]
43. Targeting the adnexal epithelium: an unusual case of syringometaplasia in a patient on vemurafenib.
Yu J; Ravikumar S; Plaza JA; Troy JL; Schieke SM
Am J Dermatopathol; 2015 May; 37(5):e57-60. PubMed ID: 25839889
[TBL] [Abstract][Full Text] [Related]
44. Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia with different clinical stages.
Gopcsa L; Barta A; Banyai A; Foldi J; Kalasz L; Pajor L; Gidali J; Regeczy N; Paloczi K
Acta Haematol; 2001; 106(3):100-5. PubMed ID: 11713374
[TBL] [Abstract][Full Text] [Related]
45. Herpetic syringitis associated with eccrine squamous syringometaplasia in HIV-positive patients.
Muñoz E; Valks R; Fernández-Herrera J; Fraga J
J Cutan Pathol; 1997 Aug; 24(7):425-8. PubMed ID: 9274960
[TBL] [Abstract][Full Text] [Related]
46. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
47. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.
Mirza AS; Lancet JE; Sweet K; Padron E; Pinilla-Ibarz J; Nardelli L; Cubitt C; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):902-907. PubMed ID: 29030092
[TBL] [Abstract][Full Text] [Related]
48. Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia.
Gandhi V; Du M; Kantarjian HM; Plunkett W
Leukemia; 1994 Sep; 8(9):1463-8. PubMed ID: 8090026
[TBL] [Abstract][Full Text] [Related]
49. [Treatment of leukemia: discussion].
Nihon Naika Gakkai Zasshi; 1992 Jul; 81(7):1081-93. PubMed ID: 1383368
[No Abstract] [Full Text] [Related]
50. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
Deau B; Nicolini FE; Guilhot J; Huguet F; Guerci A; Legros L; Pautas C; Berthou C; Guyotat D; Cony-Makhoul P; Gardembas M; Michallet M; Hayette S; Cayuela JM; Weiss IR; Réa D; Castaigne S; Mahon FX; Guilhot F; Rousselot P
Leuk Res; 2011 Jun; 35(6):777-82. PubMed ID: 21145590
[TBL] [Abstract][Full Text] [Related]
51. Mini-ICE regimen allows mobilization of peripheral blood progenitor cells in a patient with chronic myelogenous leukemia failing the ICE protocol.
Salar A; Sureda A; Menéndez B; Sierra J
Haematologica; 2000 Mar; 85(3):326-7. PubMed ID: 10702830
[No Abstract] [Full Text] [Related]
52. Idarubicin, intermediate-dose cytarabine, etoposide, and granulocyte-colony-stimulating factor are able to recruit CD34+/HLA-DR- cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia.
Carella AM; Frassoni F; Podestá M; Pungolino E; Pollicardo N; Ferrero R; Soracco M
J Hematother; 1994; 3(3):199-202. PubMed ID: 7530135
[TBL] [Abstract][Full Text] [Related]
53. Toxic erythema of chemotherapy: a useful clinical term.
Bolognia JL; Cooper DL; Glusac EJ
J Am Acad Dermatol; 2008 Sep; 59(3):524-9. PubMed ID: 18694683
[No Abstract] [Full Text] [Related]
54. A papulovesicular eruption in a man receiving chemotherapy for metastatic melanoma. Squamous syringometaplasia (squamous metaplasia) of the eccrine glands.
Wong P; Bangert JL; Levine N
Arch Dermatol; 1993 Feb; 129(2):232-3, 235-6. PubMed ID: 8434984
[No Abstract] [Full Text] [Related]
55. Clinical effect of granulocyte colony-stimulating factor on neutrophils and leukemic cells in myelogenous leukemia: analysis.
Ishikawa J; Yoshimura M; Matsunashi T; Tominaga N; Teshima H; Hiraoka A; Nakamura H; Shibata H; Masaoka T; Takaku F
Jpn J Clin Oncol; 1991 Jun; 21(3):169-75. PubMed ID: 1719259
[TBL] [Abstract][Full Text] [Related]
56. Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia.
Santopietro M; Miano M; Palumbo G; Zhang K; Cardarelli L; Chiaretti S; Peragine N; Nanni M; Diverio D; Mancini F; Testi AM; Moleti ML; Foà R; Giona F
Acta Haematol; 2019; 142(3):185-186. PubMed ID: 31112981
[No Abstract] [Full Text] [Related]
57. CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients.
Seiter K; Ahmed N; Shaikh A; Baskind P; Liu D
Leuk Res; 2016 Jul; 46():74-8. PubMed ID: 27151544
[TBL] [Abstract][Full Text] [Related]
58. Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon.
Hernández-Boluda JC; Carreras E; Cervantes F; Marín P; Arellano-Rodrigo E; Rovira M; Solé F; Lloveras E; Espinet B; Ocejo A; Montserrat E
Haematologica; 2002 Jan; 87(1):17-22. PubMed ID: 11801461
[TBL] [Abstract][Full Text] [Related]
59. Eccrine squamous syringometaplasia and cytomegalovirus.
Daudén E; Porras JI; Buezo GF; García-Díez A
Am J Dermatopathol; 2000 Dec; 22(6):559-61. PubMed ID: 11190451
[No Abstract] [Full Text] [Related]
60. Syringomatous hyperplasia and eccrine squamous syringometaplasia associated with benoxaprofen therapy.
Lerner TH; Barr RJ; Dolezal JF; Stagnone JJ
Arch Dermatol; 1987 Sep; 123(9):1202-4. PubMed ID: 3498441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
